Gly Lys Pro His Pro His Ser Phe Ile Arg Asp Ser Glu Glu Lys Arg
Asn Val Gln Val Asp Val Val Glu Gly Lys Gly Ile Asp Ile Lys Ser
Ser Leu Ser Gly Leu Thr Val Leu Lys Ser Thr Asn Ser Gln Phe Trp
Gly Phe Leu Arg Asp Glu Tyr Thr Thr Leu Lys Glu Thr Trp Asp Arg
Ile Leu Ser Thr Asp Val Asp Ala Thr Trp Gln Trp Lys Asn Phe Ser
Gly Leu Gln Glu Val Arg Ser His Val Pro Lys Phe Asp Ala Thr Trp
Ala Thr Ala Arg Glu Val Thr Leu Lys Thr Phe Ala Glu Asp Asn Ser
Ala Ser Val Gln Ala Thr Met Tyr Lys Met Ala Glu Gln Ile Leu Ala
Arg Gln Gln Leu Ile Glu Thr Val Glu Tyr Ser Leu Pro Asn Lys His
Tyr Phe Glu Ile Asp Leu Ser Trp His Lys Gly Leu Gln Asn Thr Gly
Lys Asn Ala Glu Val Phe Ala Pro Gln Ser Asp Pro Asn Gly Leu Ile
Lys Cys Thr Val Gly Arg Ser Ser Leu Lys Ser Lys Leu

preceded, if appropriate, by a methionine[, or having a substantial degree of homology with that sequence].

2. (Amended) A protein according to claim 1, [possessing a specific urate oxidase activity of at least 30 U/mg] <u>wherein said protein is produced by recombinant methods</u>.

3. (Twice amended) A protein according to claim 1 [or 2], which presents, by analysis on a bidimensional Laemmli/SDS-Agarose gel, a spot of molecular mass of about 33.5 kDa[and an isoelectric point around 8.0], representing at least 90% of the protein mass.

6. (Twice amended) A protein according to [anyone of claims 1 to 4] <u>claim 1</u>, which carries a blocking group on the amino-terminal serine.

7. (Twice amended) A pharmaceutical composition comprising a protein according to [anyone of claims 1 to 6] <u>claim 1</u>.